| Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics AC Mita, MM Mita, ST Nawrocki, FJ Giles Clinical cancer research 14 (16), 5000-5005, 2008 | 1068 | 2008 |
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas RG Maki, DR D'Adamo, ML Keohan, M Saulle, SM Schuetze, SD Undevia, ... Journal of Clinical Oncology 27 (19), 3133-3140, 2009 | 660 | 2009 |
| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 433 | 2019 |
| Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial PE Lønning, E Bajetta, R Murray, M Tubiana-Hulin, PD Eisenberg, ... Journal of Clinical Oncology 18 (11), 2234-2244, 2000 | 417 | 2000 |
| LXR/ApoE activation restricts innate immune suppression in cancer MF Tavazoie, I Pollack, R Tanqueco, BN Ostendorf, BS Reis, ... Cell 172 (4), 825-840. e18, 2018 | 392 | 2018 |
| Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor–related apoptosis … AW Tolcher, M Mita, NJ Meropol, M von Mehren, A Patnaik, K Padavic, ... Journal of Clinical Oncology 25 (11), 1390-1396, 2007 | 375 | 2007 |
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ... Clinical Cancer Research 14 (14), 4500-4510, 2008 | 345 | 2008 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 339 | 2019 |
| Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with … MM Mita, AC Mita, QS Chu, EK Rowinsky, GJ Fetterly, M Goldston, ... Journal of Clinical Oncology 26 (3), 361-367, 2008 | 315 | 2008 |
| Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC … D Mahalingam, M Mita, J Sarantopoulos, L Wood, RK Amaravadi, ... Autophagy 10 (8), 1403-1414, 2014 | 306 | 2014 |
| Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas SP Chawla, AP Staddon, LH Baker, SM Schuetze, AW Tolcher, ... Journal of Clinical Oncology 30 (1), 78-84, 2012 | 291 | 2012 |
| Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors DD Von Hoff, MM Mita, RK Ramanathan, GJ Weiss, AC Mita, PM LoRusso, ... Clinical Cancer Research 22 (13), 3157-3163, 2016 | 263 | 2016 |
| The molecular target of rapamycin (mTOR) as a therapeutic target against cancer MM Mita, A Mita, EK Rowinsky Cancer biology & therapy 2 (sup1), 168-176, 2003 | 247 | 2003 |
| Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation JS Carew, EC Medina, JA Esquivel II, D Mahalingam, R Swords, K Kelly, ... Journal of cellular and molecular medicine 14 (10), 2448-2459, 2010 | 238 | 2010 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 199 | 2022 |
| Mammalian target of rapamycin: a new molecular target for breast cancer MM Mita, A Mita, EK Rowinsky Clinical breast cancer 4 (2), 126-137, 2003 | 187 | 2003 |
| Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer MM Mita, AA Joy, A Mita, K Sankhala, YM Jou, D Zhang, P Statkevich, ... Clinical breast cancer 14 (3), 169-176, 2014 | 183 | 2014 |
| Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors HA Wakelee, A Patnaik, BI Sikic, M Mita, NL Fox, R Miceli, SJ Ullrich, ... Annals of Oncology 21 (2), 376-381, 2010 | 179 | 2010 |
| First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors C Sessa, GI Shapiro, KN Bhalla, C Britten, KS Jacks, M Mita, ... Clinical Cancer Research 19 (13), 3671-3680, 2013 | 171 | 2013 |
| A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies S Goel, AC Mita, M Mita, EK Rowinsky, QS Chu, N Wong, C Desjardins, ... Clinical Cancer Research 15 (12), 4207-4212, 2009 | 169 | 2009 |
